# Bispecific PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bispecific

> The next catalyst for bispecific, sponsored by INCYTE CORP (INCY), is its topline data readout, 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for bispecific?

The next catalyst for bispecific, sponsored by INCYTE CORP (INCY), is its topline data readout, 2029. Press release filed with the SEC (EX-99): "•A Phase 3 study (NEXERA-303) evaluating INCA33890 in combination with SoC chemotherapy and bevacizumab as a first-line treatment in patients with MSS CRC is ongoing, with topline data anticipated in 2029." [Calendar and source filings](https://sec-api.dev/pdufa/bispecific)

Source: Press release filed with the SEC (EX-99), accession 0000879169-26-000063, https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/bispecific#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | bispecific |
| Codes | INCA33890 |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications | select advanced solid tumors, select advanced/metastatic solid tumors |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: select advanced solid tumors.
- First seen 2025-02-10, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0000879169-25-000118): "In July 2023, we initiated a Phase 1 study evaluating INCA33890 in patients with select advanced/metastatic solid tumors." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "In July 2023, we initiated a Phase 1 study evaluating INCA33890 in patients with select advanced solid tumors." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In July 2023, we initiated a Phase 1 study evaluating INCA33890 in patients with select advanced solid tumors." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In July 2023, we initiated a Phase 1 study evaluating INCA33890 in patients with select advanced solid tumors." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### 2029: topline data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000063): "•A Phase 3 study (NEXERA-303) evaluating INCA33890 in combination with SoC chemotherapy and bevacizumab as a first-line treatment in patients with MSS CRC is ongoing, with topline data anticipated in 2029." https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bispecific.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Bispecific PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bispecific

```bibtex
@misc{secapidev_pdufa_bispecific_20261116,
  title        = {Bispecific PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bispecific}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bispecific_20261116","title":"Bispecific PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bispecific","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
